Masimo Corp. Stock
Masimo Corp. Stock
Pros and Cons of Masimo Corp. in the next few years
Pros
Cons
Performance of Masimo Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Masimo Corp. | - | - | - | - | - | - | - |
| Bio-Rad Labs Inc. A | 4.180% | 5.779% | 6.102% | 27.439% | 7.871% | -26.866% | -52.034% |
| CONMED Corp. | -0.530% | 0.535% | 22.876% | -10.476% | 7.429% | -65.505% | -66.726% |
| Penumbra Inc | 0.140% | 0.575% | 0.503% | 42.067% | 5.030% | 2.868% | 22.612% |
Comments
News
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition
On February 17, 2026, Bridger Management disclosed in a Securities and Exchange Commission (SEC) filing that it sold out its entire position in Masimo (NASDAQ:MASI).
According to a Securities and
This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement
On February 17, 2026, Parkman Healthcare Partners disclosed a new position in Masimo Corporation (NASDAQ:MASI), acquiring 200,000 shares in the fourth quarter worth an estimated $26.01 million at
Naya Capital Adds Masimo Shares
According to an SEC filing dated Feb. 18, Naya Capital Management UK Ltd disclosed a new position in Masimo (NASDAQ:MASI), acquiring nearly 1.6 million shares.
Masimo is a leading provider of


